Treatment Of Cognitive deficits in schizophrenia with Tolcapone And Pergolide

Pharmacotherapy of cognitive deficits in schizophrenic disorders: a randomised placebo-controlled double-blind study of tolcapone versus pergolide

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN42412532

Enrollment

Registered

2010-04-14

Start date

2010-04-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia, cognitive functions Mental and Behavioural Disorders Schizophrenia

Interventions

TOCTAP is a randomised, three-armed double-blind study with 60 patients suffering from schizophrenia, using DSM-IV diagnostic criteria. Patients are randomised in three groups of 20 patients each. Pat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 60 patients suffering from schizophrenia using Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria 2. Signed informed consent 3. Aged 18 - 55 years, either sex 4. Negative pregnancy test 5. No drug addiction 6. No suicidality 7. Ability to understand and read German language

Exclusion criteria

Exclusion criteria: 1. Drug addiction 2. Severe medical problems 3. Long-QT-syndrome 4. Problems regarding the heart-valves 5. Seizures 6. Reduced liver or renal function 7. Pregnancy 8. Known incompatibility of the study-drugs

Design outcomes

Primary

Measure	Time frame
Change in Matrics Consensus Cognitive Battery (MCCB), tested at baseline and after a treatment period of six weeks	—

Secondary

Measure	Time frame
Improvement of clinical outcome regarding schizophrenic symptoms, tested at baseline and after a treatment period of six weeks	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026